Argenx's Forte Bio Deal Validates CEO Change

Dow Jones

Jul 28

0823 GMT - Argenx's $2.2 billion deal to acquire Forte Biosciences should help the European pharmaceutical company diversify its portfolio and validates a CEO transition that took place earlier this year, Bernstein analysts say in a note. Argenx currently has one successful growth driver, its Vyvgart drug for rare neuromuscular disease myasthenia gravis, but its U.S. patent is due to expire in 2036, the analysts say. The next five years are key for broadening and deepening its pipeline, and the Forte deal helps it lower portfolio-concentration risk, they add. "Moreover, a key reason why [Argenx] underwent its CEO transition in [January] was to try to accelerate complementing its organic pipeline with interesting external assets," Bernstein says. Argenx's shares fall 0.7%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 28, 2026 04:23 ET (08:23 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2654518072"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2654518072\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2654518072?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-28 16:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654518072","market":"fut","top_or_hot":-1,"title":"Argenx's Forte Bio Deal Validates CEO Change","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0823 GMT - Argenx's $2.2 billion deal to acquire Forte Biosciences should help the European pharmaceutical company diversify its portfolio and validates a CEO transition that took place earlier this year, Bernstein analysts say in a note. Argenx currently has one successful growth driver, its Vyvgart drug for rare neuromuscular disease myasthenia gravis, but its U.S. patent is due to expire in 2036, the analysts say. The next five years are key for broadening and deepening its pipeline, and the Forte deal helps it lower portfolio-concentration risk, they add. \"Moreover, a key reason why [Argenx] underwent its CEO transition in [January] was to try to accelerate complementing its organic pipeline with interesting external assets,\" Bernstein says. Argenx's shares fall 0.7%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 28, 2026 04:23 ET (08:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Argenx's Forte Bio Deal Validates CEO Change</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArgenx's Forte Bio Deal Validates CEO Change\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-28 16:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0823 GMT - Argenx's $2.2 billion deal to acquire Forte Biosciences should help the European pharmaceutical company diversify its portfolio and validates a CEO transition that took place earlier this year, Bernstein analysts say in a note. Argenx currently has one successful growth driver, its Vyvgart drug for rare neuromuscular disease myasthenia gravis, but its U.S. patent is due to expire in 2036, the analysts say. The next five years are key for broadening and deepening its pipeline, and the Forte deal helps it lower portfolio-concentration risk, they add. \"Moreover, a key reason why [Argenx] underwent its CEO transition in [January] was to try to accelerate complementing its organic pipeline with interesting external assets,\" Bernstein says. Argenx's shares fall 0.7%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 28, 2026 04:23 ET (08:23 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2654518072","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654518072","pubTimestamp":1785226980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0823 GMT - Argenx's $2.2 billion deal to acquire Forte Biosciences should help the European pharmaceutical company diversify its portfolio and validates a CEO transition that took place earlier this year, Bernstein analysts say in a note. Argenx currently has one successful growth driver, its Vyvgart drug for rare neuromuscular disease myasthenia gravis, but its U.S. patent is due to expire in 2036, the analysts say. The next five years are key for broadening and deepening its pipeline, and the Forte deal helps it lower portfolio-concentration risk, they add. \"Moreover, a key reason why [Argenx] underwent its CEO transition in [January] was to try to accelerate complementing its organic pipeline with interesting external assets,\" Bernstein says. Argenx's shares fall 0.7%.  Dow Jones NewswiresJuly 28, 2026 04:23 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","ARGX":"Argenx SE","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4505":"高瓴资本持仓","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IBB":"生物科技指数ETF-iShares Nasdaq","BK4588":"碎股","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","FMED":"Fidelity Disruptive Medicine ETF","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","FBRX":"Forte BioSciences Inc","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1983260115.SGD":"Janus Henderson Horizon Global Sustainable Equity A2 SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"Argenx 的 Forte Bio 交易验证了首席执行官变更","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FBRX":0.9,"ARGX":0.9,"TBXU":0.6,"IBB":0.6,"FMED":0.6},"content_text":"0823 GMT - Argenx's $2.2 billion deal to acquire Forte Biosciences should help the European pharmaceutical company diversify its portfolio and validates a CEO transition that took place earlier this year, Bernstein analysts say in a note. Argenx currently has one successful growth driver, its Vyvgart drug for rare neuromuscular disease myasthenia gravis, but its U.S. patent is due to expire in 2036, the analysts say. The next five years are key for broadening and deepening its pipeline, and the Forte deal helps it lower portfolio-concentration risk, they add. \"Moreover, a key reason why [Argenx] underwent its CEO transition in [January] was to try to accelerate complementing its organic pipeline with interesting external assets,\" Bernstein says. Argenx's shares fall 0.7%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 28, 2026 04:23 ET (08:23 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}